Metals in alzheimer's disease: A systemic perspective

Frontiers in Bioscience

Volumn 17, Issue 2, 2012, Pages 451-472

  Squitti, Rosanna ^a,b  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Alzheimer's disease; Antioxidant status; Ceruloplasmin; Copper; Ferritin; Hemochromatosis; HFE; Iron; Metals; Oxidative stress; Review; Transferrin

Indexed keywords

ANIMALIA;

EID: 84858982731     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3938     Document Type: Review

References (160)

1. A. I. Bush and R. E. Tanzi: Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics, 5(3), 421-32 (2008). (Pubitemid 351952485)
2. A. I. Bush: The metallobiology of Alzheimer's disease. Trends Neurosci, 26(4), 207-14 (2003). (Pubitemid 36412003)
3. R. Danzeisen, M. Araya, B. Harrison, C. Keen, M. Solioz, D. Thiele and H. J. McArdle: How reliable and robust are current biomarkers for copper status? Br J Nutr, 98(4), 676-83 (2007). (Pubitemid 47487934)
4. I. Bremner: Copper toxicity studies using domestic and laboratory animals. In: Copper in the environment. Part II: health effects. Ed J. O. Nriagu. John Wiley & Sons, New York (1979).
5. M. C. Linder, P. A. Houle, E. Isaacs, J. R. Moor and L. E. Scott: Copper regulation of ceruloplasmin in copperdeficient rats. Enzyme, 24(1), 23-35 (1979). (Pubitemid 9104724)
6. J. G. Chutkow: Evidence for uptake of nonceruloplasminic copper in the brain: effect of ionic copper and amino acids. Proc Soc Exp Biol Med, 158(1), 113-6 (1978). (Pubitemid 8375724)
7. B. S. Choi and W. Zheng: Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res, 1248, 14-21 (2009).
8. P. Bielli and L. Calabrese: Structure to function relationships in ceruloplasmin: a 'moonlighting' protein. Cell Mol Life Sci, 59(9), 1413-27 (2002). (Pubitemid 35239300)
9. B. N. Patel, R. J. Dunn, S. Y. Jeong, Q. Zhu, J. P. Julien and S. David: Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci, 22(15), 6578-86 (2002). (Pubitemid 35386414)
10. B. E. Kim, T. Nevitt and D. J. Thiele: Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol, 4(3), 176-85 (2008). (Pubitemid 351264130)
11. R. D. Palmiter: Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc Natl Acad Sci U S A, 91(4), 1219-23 (1994). (Pubitemid 24058981)
12. J. Durand, G. Meloni, C. Talmard, M. Vasak and P. Faller: Zinc release of Zn-metallothionein-3 induces fibrillar type amyloid-beta aggregates. Metallomics, 2(11), 741-4 (2010).
13. G. Meloni, V. Sonois, T. Delaine, L. Guilloreau, A. Gillet, J. Teissie, P. Faller and M. Vasak: Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat Chem Biol, 4(6), 366-72 (2008). (Pubitemid 351693994)
14. W. H. Yu, W. J. Lukiw, C. Bergeron, H. B. Niznik and P. E. Fraser: Metallothionein III is reduced in Alzheimer's disease. Brain Res, 894(1), 37-45 (2001). (Pubitemid 32197596)
15. L. Rossi, M. R. Ciriolo, E. Marchese, A. De Martino, M. Giorgi and G. Rotilio: Differential decrease of copper content and of copper binding to superoxide dismutase in liver, heart and brain of copper-deficient rats. Biochem Biophys Res Commun, 203(2), 1028-34 (1994). (Pubitemid 24304932)
16. D. J. Selkoe: The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol Clin, 18(4), 903-22 (2000).
17. C. Priller, T. Bauer, G. Mitteregger, B. Krebs, H. A. Kretzschmar and J. Herms: Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci, 26(27), 7212-21 (2006).
18. J. A. Duce, A. Tsatsanis, M. A. Cater, S. A. James, E. Robb, K. Wikhe, S. L. Leong, K. Perez, T. Johanssen, M. A. Greenough, H. H. Cho, D. Galatis, R. D. Moir, C. L. Masters, C. McLean, R. E. Tanzi, R. Cappai, K. J. Barnham, G. D. Ciccotosto, J. T. Rogers and A. I. Bush: Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 142(6), 857-67 (2010).
19. A. R. White, R. Reyes, J. F. Mercer, J. Camakaris, H. Zheng, A. I. Bush, G. Multhaup, K. Beyreuther, C. L. Masters and R. Cappai: Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res, 842(2), 439-44 (1999). (Pubitemid 29475178)
20. R. Squitti and G. Zito: Anti-copper therapies in Alzheimer's disease: new concepts. Recent Pat CNS Drug Discov, 4(3), 209-19 (2009).
21. S. A. Bellingham, G. D. Ciccotosto, B. E. Needham, L. R. Fodero, A. R. White, C. L. Masters, R. Cappai and J. Camakaris: Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem, 91(2), 423-8 (2004). (Pubitemid 39363441)
22. S. A. Bellingham, D. K. Lahiri, B. Maloney, S. La Fontaine, G. Multhaup and J. Camakaris: Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem, 279(19), 20378-86 (2004). (Pubitemid 38623484)
23. D. S. Jacobs, D. K. Oxley and W. R. DeMott: Laboratory Test Handbook: Concise With Disease Index (Laboratory Test Handbook Concise). Cleveland (2002).
24. G. J. Brewer: Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood), 232(2), 323-35 (2007). (Pubitemid 46203301)
25. S. Bucossi, M. Ventriglia, V. Panetta, C. Salustri, P. Pasqualetti, S. Mariani, M. Siotto, P. M. Rossini and R. Squitti: Copper in Alzheimer's disease: a meta-analysis of serum, plasma and cerebrospinal studies. J Alzheimers Dis [Epub ahead of print] (2010).
26. R. Ozcankaya and N. Delibas: Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J, 43(1), 28-32 (2002). (Pubitemid 34157862)
27. H. Vural, H. Demirin, Y. Kara, I. Eren and N. Delibas: Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol, 24(3), 169-73 (2010).
28. B. Halliwell and J. M. Gutteridge: Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol, 186, 1-85 (1990). (Pubitemid 20279941)
29. C. R. Capo, M. Arciello, R. Squitti, E. Cassetta, P. M. Rossini, L. Calabrese and L. Rossi: Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals, 21(3), 367-72 (2008).
30. E. D. Harris: Cellular copper transport and metabolism. Annu Rev Nutr, 20, 291-310 (2000).
31. Y. Qian, E. Tiffany-Castiglioni, J. Welsh and E. D. Harris: Copper efflux from murine microvascular cells requires expression of the menkes disease Cu-ATPase. J Nutr, 128(8), 1276-82 (1998). (Pubitemid 28361417)
32. V. Iyengar, G. J. Brewer, R. D. Dick and O. Y. Chung: Studies of cholecystokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson's disease. J Lab Clin Med, 111(3), 267-74 (1988). (Pubitemid 18082750)
33. D. E. Hartter and A. Barnea: Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J Biol Chem, 263(2), 799-805 (1988). (Pubitemid 18044707)
34. M. A. Deibel, W. D. Ehmann and W. R. Markesbery: Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci, 143(1, 2), 137-42 (1996). (Pubitemid 26402800)
35. C. J. Maynard, R. Cappai, I. Volitakis, R. A. Cherny, A. R. White, K. Beyreuther, C. L. Masters, A. I. Bush and Q. X. Li: Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem, 277(47), 44670-6 (2002). (Pubitemid 36159056)
36. D. A. Loeffler, A. J. DeMaggio, P. L. Juneau, C. M. Brickman, G. A. Mashour, J. H. Finkelman, N. Pomara and P. A. LeWitt: Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord, 8(3), 190-7 (1994). (Pubitemid 24282548)
37. M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell and W. R. Markesbery: Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci, 158(1), 47-52 (1998). (Pubitemid 28277534)
38. E. Barry, T. Derhammer and S. H. Elsea: Prevalence of three hereditary hemochromatosis mutant alleles in the Michigan Caucasian population. Community Genet, 8(3), 173-9 (2005). (Pubitemid 41197100)
39. Z. J. Bulaj, R. S. Ajioka, J. D. Phillips, B. A. LaSalle, L. B. Jorde, L. M. Griffen, C. Q. Edwards and J. P. Kushner: Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med, 343(21), 1529-35 (2000).
40. E. Mills, X. Dong, F. Wang and Xu, H. Mechanisms of Brian Transport: Insight ito Neurodegeneration and CNS Disorders. Future Med Chem, 2(1), 51 (2010).
41. G. L. Wenk, K. McGann, B. Hauss-Wegrzyniak and S. Rosi: The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. Neuroscience, 121(3), 719-29 (2003). (Pubitemid 38367510)
42. P. J. Crouch, A. R. White and A. I. Bush: The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J, 274(15), 3775-83 (2007). (Pubitemid 47087674)
43. P. V. Arriagada, J. H. Growdon, E. T. Hedley-Whyte and B. T. Hyman: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 42(3 Pt 1), 631-9 (1992).
44. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E. M. Stadlan: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34(7), 939-44 (1984). (Pubitemid 14076461)
45. B. Dubois, H. H. Feldman, C. Jacova, S. T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, K. Meguro, J. O'Brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P. J. Visser and P. Scheltens: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol, 6(8), 734-46 (2007). (Pubitemid 47058377)
46. C. S. Atwood, R. D. Moir, X. Huang, R. C. Scarpa, N. M. Bacarra, D. M. Romano, M. A. Hartshorn, R. E. Tanzi and A. I. Bush: Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem, 273(21), 12817-26 (1998). (Pubitemid 28246837)
47. R. A. Cherny, C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. McLean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y. Kim, X. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters and A. I. Bush: Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30(3), 665-76 (2001). (Pubitemid 32607332)
48. R. A. Cherny, J. T. Legg, C. A. McLean, D. P. Fairlie, X. Huang, C. S. Atwood, K. Beyreuther, R. E. Tanzi, C. L. Masters and A. I. Bush: Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem, 274(33), 23223-8 (1999).
49. X. Huang, C. S. Atwood, M. A. Hartshorn, G. Multhaup, L. E. Goldstein, R. C. Scarpa, M. P. Cuajungco, D. N. Gray, J. Lim, R. D. Moir, R. E. Tanzi and A. I. Bush: The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry, 38(24), 7609-16 (1999). (Pubitemid 29289332)
50. X. Huang, M. P. Cuajungco, C. S. Atwood, M. A. Hartshorn, J. D. Tyndall, G. R. Hanson, K. C. Stokes, M. Leopold, G. Multhaup, L. E. Goldstein, R. C. Scarpa, A. J. Saunders, J. Lim, R. D. Moir, C. Glabe, E. F. Bowden, C. L. Masters, D. P. Fairlie, R. E. Tanzi and A. I. Bush: Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem, 274(52), 37111-6 (1999).
51. D. Edbauer, E. Winkler, J. T. Regula, B. Pesold, H. Steiner and C. Haass: Reconstitution of gammasecretase activity. Nat Cell Biol, 5(5), 486-8 (2003).
52. B. Angeletti, K. J. Waldron, K. B. Freeman, H. Bawagan, I. Hussain, C. C. Miller, K. F. Lau, M. E. Tennant, C. Dennison, N. J. Robinson and C. Dingwall: BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem, 280(18), 17930-7 (2005). (Pubitemid 41389034)
53. R. Lin, X. Chen, W. Li, Y. Han, P. Liu and R. Pi: Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. Neurosci Lett, 440(3), 344-7 (2008).
54. P. J. Crouch, R. Blake, J. A. Duce, G. D. Ciccotosto, Q. X. Li, K. J. Barnham, C. C. Curtain, R. A. Cherny, R. Cappai, T. Dyrks, C. L. Masters and I. A. Trounce: Copperdependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci, 25(3), 672-9 (2005).
55. A. D. Armendariz, M. Gonzalez, A. V. Loguinov and C. D. Vulpe: Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol Genomics, 20(1), 45-54 (2004). (Pubitemid 40388504)
56. Q. Ma, Y. Li, J. Du, H. Liu, K. Kanazawa, T. Nemoto, H. Nakanishi and Y. Zhao: Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides, 27(4), 841-9 (2006).
57. L. M. Sayre, G. Perry, P. L. Harris, Y. Liu, K. A. Schubert and M. A. Smith: In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem, 74(1), 270-9 (2000). (Pubitemid 30012778)
58. M. Miyata and J. D. Smith: Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet, 14(1), 55-61 (1996). (Pubitemid 26301547)
59. R. D. Moir, C. S. Atwood, D. M. Romano, M. H. Laurans, X. Huang, A. I. Bush, J. D. Smith and R. E. Tanzi: Differential effects of apolipoprotein E isoforms on metalinduced aggregation of A beta using physiological concentrations. Biochemistry, 38(14), 4595-603 (1999).
60. D. A. Sanan, K. H. Weisgraber, S. J. Russell, R. W. Mahley, D. Huang, A. Saunders, D. Schmechel, T. Wisniewski, B. Frangione, A. D. Roses and et al.: Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest, 94(2), 860-9 (1994).
61. C. Gonzalez, T. Martin, J. Cacho, M. T. Brenas, T. Arroyo, B. Garcia-Berrocal, J. A. Navajo and J. M. Gonzalez-Buitrago: Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest, 29(7), 637-42 (1999). (Pubitemid 29322377)
62. R. Squitti, D. Lupoi, P. Pasqualetti, G. Dal Forno, F. Vernieri, P. Chiovenda, L. Rossi, M. Cortesi, E. Cassetta and P. M. Rossini: Elevation of serum copper levels in Alzheimer's disease. Neurology, 59(8), 1153-61 (2002). (Pubitemid 35192384)
63. R. Squitti, M. Ventriglia, G. Barbati, E. Cassetta, F. Ferreri, G. Dal Forno, S. Ramires, F. Zappasodi and P. M. Rossini: 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm, 114(12), 1589-94 (2007). (Pubitemid 350212005)
64. C. Babiloni, R. Squitti, C. Del Percio, E. Cassetta, M. C. Ventriglia, F. Ferreri, M. Tombini, G. Frisoni, G. Binetti, M. Gurzi, S. Salinari, F. Zappasodi and P. M. Rossini: Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clin Neurophysiol, 118(6), 1244-60 (2007). (Pubitemid 46736024)
65. F. Zappasodi, C. Salustri, C. Babiloni, E. Cassetta, C. Del Percio, M. Ercolani, P. M. Rossini and R. Squitti: An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res, 1215, 183-9 (2008).
66. C. Babiloni, P. Bosco, R. Ghidoni, C. Del Percio, R. Squitti, G. Binetti, L. Benussi, R. Ferri, G. Frisoni, B. Lanuzza, E. Cassetta, G. Anello, M. Gurzi, S. Bartesaghi, R. Lizio, M. Tombini and P. M. Rossini: Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study. Neuroscience, 145(3), 942-54 (2007). (Pubitemid 46454356)
67. G. Gorgone, D. Caccamo, L. R. Pisani, M. Curro, G. Parisi, G. Oteri, R. Ientile, P. M. Rossini and F. Pisani: Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia, 50 Suppl 1, 33-6 (2009).
68. E. Nakano, M. P. Williamson, N. H. Williams and H. J. Powers: Copper-mediated LDL oxidation by homocysteine and related compounds depends largely on copper ligation. Biochim Biophys Acta, 1688(1), 33-42 (2004). (Pubitemid 38372098)
69. L. Puglielli, A. L. Friedlich, K. D. Setchell, S. Nagano, C. Opazo, R. A. Cherny, K. J. Barnham, J. D. Wade, S. Melov, D. M. Kovacs and A. I. Bush: Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest, 115(9), 2556-63 (2005). (Pubitemid 41266218)
70. T. J. Nelson and D. L. Alkon: Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem, 280(8), 7377-87 (2005). (Pubitemid 40341296)
71. D. L. Sparks and B. G. Schreurs: Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A, 100(19), 11065-9 (2003). (Pubitemid 37140153)
72. C. Opazo, X. Huang, R. A. Cherny, R. D. Moir, A. E. Roher, A. R. White, R. Cappai, C. L. Masters, R. E. Tanzi, N. C. Inestrosa and A. I. Bush: Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem, 277(43), 40302-8 (2002). (Pubitemid 35215603)
73. D. L. Sparks, R. Friedland, S. Petanceska, B. G. Schreurs, J. Shi, G. Perry, M. A. Smith, A. Sharma, S. Derosa, C. Ziolkowski and G. Stankovic: Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging, 10(4), 247-54 (2006). (Pubitemid 44351819)
74. M. C. Morris, D. A. Evans, C. C. Tangney, J. L. Bienias, J. A. Schneider, R. S. Wilson and P. A. Scherr: Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol, 63(8), 1085-8 (2006). (Pubitemid 44232313)
75. A. I. Bush, C. L. Masters and R. E. Tanzi: Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc Natl Acad Sci U S A, 100(20), 11193-4 (2003). (Pubitemid 37205909)
76. P. K. Lam, D. Kritz-Silverstein, E. Barrett Connor, D. Milne, F. Nielsen, A. Gamst, D. Morton and D. Wingard: Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study. J Nutr Health Aging, 12(1), 22-7 (2008). (Pubitemid 351156011)
77. C. J. Maynard, A. I. Bush, C. L. Masters, R. Cappai and Q. X. Li: Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol, 86(3), 147-59 (2005).
78. R. Agarwal, S. S. Kushwaha, C. B. Tripathi, N. Singh and N. Chhillar: Serum copper in Alzheimer's disease and vascular dementia Indian Journal of Clinical Biochemistry, 23 (4), 369-374 (2008).
79. N. Arnal, D. O. Cristalli, M. J. de Alaniz and C. A. Marra: Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res (2009).
80. B. Bocca, G. Forte, F. Petrucci, A. Pino, F. Marchione, G. Bomboi, O. Senofonte, F. Giubilei and A. Alimonti: Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita, 41(2), 197-203 (2005). (Pubitemid 43169864)
81. U. O. Sevym S, Tamer I, Dǒgu O, Ozge A.: Can serum levels of copper and zinc distinguish Alzheimer's patients from normal subjects? Journal of Neurological Sciences (Turkish), 24(3), 197-205 (2007). (Pubitemid 47521082)
82. C. Smorgon, E. Mari, A. R. Atti, E. Dalla Nora, P. F. Zamboni, F. Calzoni, A. Passaro and R. Fellin: Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr Suppl(9), 393-402 (2004). (Pubitemid 38822890)
83. R. Squitti, G. Barbati, L. Rossi, M. Ventriglia, G. Dal Forno, S. Cesaretti, F. Moffa, I. Caridi, E. Cassetta, P. Pasqualetti, L. Calabrese, D. Lupoi and P. M. Rossini: Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and htau. Neurology, 67(1), 76-82 (2006). (Pubitemid 44305465)
84. R. Squitti, F. Bressi, P. Pasqualetti, C. Bonomini, R. Ghidoni, G. Binetti, E. Cassetta, F. Moffa, M. Ventriglia, F. Vernieri and P. M. Rossini: Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology, 72(1), 50-5 (2009) doi:72/1/50.
85. R. Squitti, P. Pasqualetti, E. Cassetta, G. Dal Forno, S. Cesaretti, F. Pedace, A. Finazzi-Agro and P. M. Rossini: Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology, 60(12), 2013-4 (2003). (Pubitemid 36736031)
86. H. Basun, L. G. Forssell, L. Wetterberg and B. Winblad: Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect, 3(4), 231- 58 (1991).
87. L. Baum, I. H. Chan, S. K. Cheung, W. B. Goggins, V. Mok, L. Lam, V. Leung, E. Hui, C. Ng, J. Woo, H. F. Chiu, B. C. Zee, W. Cheng, M. H. Chan, S. Szeto, V. Lui, J. Tsoh, A. I. Bush, C. W. Lam and T. Kwok: Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals, 23(1), 173-9 (2010).
88. L. Gerhardsson, T. Lundh, L. Minthon and E. Londos: Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord, 25(6), 508-15 (2008). (Pubitemid 351957413)
89. C. Jeandel, M. B. Nicolas, F. Dubois, F. Nabet- Belleville, F. Penin and G. Cuny: Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology, 35(5-6), 275-82 (1989). (Pubitemid 20015238)
90. E. Kapaki, J. Segditsa, C. Zournas, D. Xenos and C. Papageorgiou: Determination of cerebrospinal fluid and serum lead levels in patients with amyotrophic lateral sclerosis and other neurological diseases. Experientia, 45(11-12), 1108-10 (1989). (Pubitemid 20007925)
91. G. Mattiello, M. Gerotto, M. Favarato, F. Lazzri, G. Gasparoni, L. Gomirato, G. Mazzolini, G. Scarpa, V. Zanaboni, M. G. Pilone and P. F. Zatta: Plasma Microelement Analysis from Alzheimer's and Multiinfartual Dementia Patients Alzheimer's Diseases: Advances in Clinical and Basic Research (1993).
92. J. A. Molina, F. J. Jimenez-Jimenez, M. V. Aguilar, I. Meseguer, C. J. Mateos-Vega, M. J. Gonzalez-Munoz, F. de Bustos, J. Porta, M. Orti-Pareja, M. Zurdo, E. Barrios and M. C. Martinez-Para: Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm, 105(4, 5), 479-88 (1998). (Pubitemid 28365030)
93. B. Sedighi, M. A. Shafa and M. Shariati: A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia, 11, 107-109 (2006).
94. J. Snaedal, J. Kristinsson, S. Gunnarsdottir, Olafsdottir, M. Baldvinsson and T. Johannesson: Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. a case-control study. Dement Geriatr Cogn Disord, 9(5), 239-42 (1998). (Pubitemid 28377223)
95. G. J. Brewer, S. H. Kanzer, E. A. Zimmerman, D. F. Celmins, S. M. Heckman and R. Dick: Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen, 25(6), 490-7 (2010).
96. H. Kessler, F. G. Pajonk, P. Meisser, T. Schneider- Axmann, K. H. Hoffmann, T. Supprian, W. Herrmann, R. Obeid, G. Multhaup, P. Falkai and T. A. Bayer: Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J Neural Transm, 113(11), 1763-9 (2006). (Pubitemid 44657672)
97. F. G. Pajonk, H. Kessler, T. Supprian, P. Hamzei, D. Bach, J. Schweickhardt, W. Herrmann, R. Obeid, A. Simons, P. Falkai, G. Multhaup and T. A. Bayer: Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimers Dis, 8(1), 23-7 (2005). (Pubitemid 41267320)
98. L. Rossi, R. Squitti, P. Pasqualetti, E. Marchese, E. Cassetta, E. Forastiere, G. Rotilio, P. M. Rossini and A. Finazzi-Agro: Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. Neurosci Lett, 329(2), 137- 40 (2002). (Pubitemid 34880058)
99. R. Squitti, E. Cassetta, G. Dal Forno, D. Lupoi, G. Lippolis, F. Pauri, F. Vernieri, A. Cappa and P. M. Rossini: Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment. Arch Neurol, 61(5), 738- 43 (2004). (Pubitemid 38637692)
100. R. Squitti, P. Pasqualetti, G. Dal Forno, F. Moffa, E. Cassetta, D. Lupoi, F. Vernieri, L. Rossi, M. Baldassini and P. M. Rossini: Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology, 64(6), 1040-6 (2005) doi:64/6/1040. (Pubitemid 40388458)
101. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G. M. Cole, N. R. Cooper, P. Eikelenboom, M. Emmerling, B. L. Fiebich, C. E. Finch, S. Frautschy, W. S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I. R. Mackenzie, P. L. McGeer, M. K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F. L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk and T. Wyss-Coray: Inflammation and Alzheimer's disease. Neurobiol Aging, 21(3), 383-421 (2000). (Pubitemid 30349107)
102. J. M. Walshe: Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem, 40(Pt 2), 115-21 (2003). (Pubitemid 36359861)
103. J. S. Althaus, J. F. Quinn, J. A. Kaye, D. A. Newsome, C. L. Bisgaier and S. H. Kanzer: Free copper measured directly in serum using a novel device is elevated in Alzheimer's disease. Invest Ophthalmol Vis Sci, 49(Eabstract ), 5218 (2008).
104. T. U. Hoogenraad: Measuring hypercupremia in blood of patients with Alzheimer's disease is logical, but the utility of measuring free-copper has to be proven. Tijdschrift voor, Utrechts (2007).
105. M. C. Boll, M. Alcaraz-Zubeldia, S. Montes and C. Rios: Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res, 33(9), 1717-23 (2008).
106. R. Squitti, R. Ghidoni, F. Scrascia, L. Benussi, V. Panetta, P. Pasqualetti, F. Moffa, S. Bernardini, V. Mariacarla, G. Binetti and P. M. Rossini: Free Copper Distinguishes Mild Cognitive Impairment Subjects From Healthy Elderly Individuals. J Alzheimers Dis (2010).
107. M. Siotto, S. Bucossi and R. Squitti: Copper status abnormalities and how to measure them in neurodegenerative disorders. Recent Pat CNS Drug Discov, 5(3), 182-94 (2010).
108. R. Squitti, C. C. Quattrocchi, C. Salustri and P. M. Rossini: Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion, 2(1), 23-7 (2008).
109. F. Giambattistelli, S. Bucossi, C. Salustri, V. Panetta, S. Mariani, M. Siotto, F. Vernieri, M. Dell'Acqua, E. Cassetta, P. M. Rossini and R. Squitti: Effects of Hemochromatosis (HFE) and Transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. submitted (2010).
110. R. Squitti and C. Salustri: Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res, 6(6), 476-87 (2009) doi:CAR- 24 [pii].
111. D. Strozyk, L. J. Launer, P. A. Adlard, R. A. Cherny, A. Tsatsanis, I. Volitakis, K. Blennow, H. Petrovitch, L. R. White and A. I. Bush: Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging, 30(7), 1069-77 (2009).
112. M. F. Folstein, S. E. Folstein and P. R. McHugh: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12(3), 189-98 (1975).
113. C. Salustri, G. Barbati, R. Ghidoni, L. Quintiliani, S. Ciappina, G. Binetti and R. Squitti: Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol, 121(4), 502-7 (2010).
114. G. J. Brewer: The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. J Am Coll Nutr, 28(3), 238-42 (2009).
115. G. Dal Forno, M. T. Palermo, J. E. Donohue, H. Karagiozis, A. B. Zonderman and C. H. Kawas: Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol, 57(3), 381-7 (2005). (Pubitemid 40343960)
116. C. Salustri, R. Squitti, F. Zappasodi, M. Ventriglia, M. G. Bevacqua, M. Fontana and F. Tecchio: Oxidative stress and brain glutamate-mediated excitability in depressed patients. J Affect Disord, 127(1- 3), 321-5 (2010) doi:S0165-0327(10)00397-6.
117. M. A. Smith, X. Zhu, M. Tabaton, G. Liu, D. W. McKeel, Jr., M. L. Cohen, X. Wang, S. L. Siedlak, B. E. Dwyer, T. Hayashi, M. Nakamura, A. Nunomura and G. Perry: Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis, 19(1), 363-72 (2010).
118. G. Bartzokis, D. Sultzer, J. Cummings, L. E. Holt, D. B. Hance, V. W. Henderson and J. Mintz: In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry, 57(1), 47-53 (2000). (Pubitemid 30035658)
119. G. Bartzokis and T. A. Tishler: MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand), 46(4), 821-33 (2000).
120. P. F. Good, D. P. Perl, L. M. Bierer and J. Schmeidler: Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol, 31(3), 286-92 (1992).
121. D. A. Loeffler, P. A. LeWitt, P. L. Juneau, A. A. Sima, H. U. Nguyen, A. J. DeMaggio, C. M. Brickman, G. J. Brewer, R. D. Dick, M. D. Troyer and L. Kanaley: Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res, 738(2), 265-74 (1996). (Pubitemid 26378921)
122. R. J. Castellani, M. A. Smith, A. Nunomura, P. L. Harris and G. Perry: Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med, 26(11, 12), 1508-12 (1999). (Pubitemid 29302284)
123. J. R. Connor, B. S. Snyder, J. L. Beard, R. E. Fine and E. J. Mufson: Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res, 31(2), 327-35 (1992).
124. A. V. Kozlov, V. I. Sergienko, A. Vladimirov Iu and O. A. Azizova: [The antioxidant system of transferrinceruloplasmin in experimental hypercholesterolemia]. Biull Eksp Biol Med, 98(12), 668-71 (1984).
125. R. Squitti, C. Salustri, M. Siotto, M. Ventriglia, F. Vernieri, D. Lupoi, E. Cassetta and P. M. Rossini: Ceruloplasmin/Transferrin Ratio Changes in Alzheimer's Disease. Int J Alzheimers Dis, 2010 Dec 27;2011:231595).
126. T. Hoogenraad: Wilson's disease. Intermed Medical Publishers Amsterdam/Rotterdam (2001).
127. K. A. Price, P. J. Crouch and A. R. White: Therapeutic treatment of Alzheimer's disease using metal complexing agents. Recent Pat CNS Drug Discov, 2(3), 180-7 (2007). (Pubitemid 350200290)
128. G. Liu, P. Men, G. Perry and M. A. Smith: Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol, 610, 123-44 (2010).
129. J. A. Duce and A. I. Bush: Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol, 92(1), 1-18 (2010).
130. M. L. Hegde, P. Bharathi, A. Suram, C. Venugopal, R. Jagannathan, P. Poddar, P. Srinivas, K. Sambamurti, K. J. Rao, J. Scancar, L. Messori, L. Zecca and P. Zatta: Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis, 17(3), 457-68 (2009).
131. X. Huang, C. S. Atwood, R. D. Moir, M. A. Hartshorn, J. P. Vonsattel, R. E. Tanzi and A. I. Bush: Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem, 272(42), 26464-70 (1997). (Pubitemid 27458865)
132. C. S. Atwood, G. Perry, H. Zeng, Y. Kato, W. D. Jones, K. Q. Ling, X. Huang, R. D. Moir, D. Wang, L. M. Sayre, M. A. Smith, S. G. Chen and A. I. Bush: Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry, 43(2), 560-8 (2004). (Pubitemid 38082580)
133. J. Y. Lee, J. E. Friedman, I. Angel, A. Kozak and J. Y. Koh: The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging, 25(10), 1315-21 (2004). (Pubitemid 39299169)
134. A. Dedeoglu, K. Cormier, S. Payton, K. A. Tseitlin, J. N. Kremsky, L. Lai, X. Li, R. D. Moir, R. E. Tanzi, A. I. Bush, N. W. Kowall, J. T. Rogers and X. Huang: Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol, 39(11-12), 1641-9 (2004) doi:S0531- 5565(04)00279-7. (Pubitemid 39585199)
135. J. F. Quinn, C. J. Harris, K. E. Cobb, C. Domes, M. Ralle, G. Brewer and T. L. Wadsworth: A copperlowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis, 21(3), 903-14 (2010).
136. P. S. Donnelly, A. Caragounis, T. Du, K. M. Laughton, I. Volitakis, R. A. Cherny, R. A. Sharples, A. F. Hill, Q. X. Li, C. L. Masters, K. J. Barnham and A. R. White: Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem, 283(8), 4568-77 (2008).
137. L. Reznichenko, T. Amit, H. Zheng, Y. Avramovich-Tirosh, M. B. Youdim, O. Weinreb and S. Mandel: Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3- gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem, 97(2), 527-36 (2006).
138. G. Liu, M. R. Garrett, P. Men, X. Zhu, G. Perry and M. A. Smith: Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta, 1741(3), 246-52 (2005). (Pubitemid 41338670)
139. G. P. Lim, T. Chu, F. Yang, W. Beech, S. A. Frautschy and G. M. Cole: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci, 21(21), 8370-7 (2001). (Pubitemid 33051435)
140. H. P. Ammon and M. A. Wahl: Pharmacology of Curcuma longa. Planta Med, 57(1), 1-7 (1991).
141. A. S. Baldwin: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest, 107(3), 241-6 (2001). (Pubitemid 32157954)
142. G. M. Cole, B. Teter and S. A. Frautschy: Neuroprotective effects of curcumin. Adv Exp Med Biol, 595, 197-212 (2007).
143. Y. Jiao, J. t. Wilkinson, E. Christine Pietsch, J. L. Buss, W. Wang, R. Planalp, F. M. Torti and S. V. Torti: Iron chelation in the biological activity of curcumin. Free Radic Biol Med, 40(7), 1152-60 (2006).
144. T. M. Di Mauro: Use of nitrogen-containing curcumin analogs for thetreatment of Alzheimer's disease. US20090326275 (2009) (2009).
145. D. R. Crapper McLachlan, A. J. Dalton, T. P. Kruck, M. Y. Bell, W. L. Smith, W. Kalow and D. F. Andrews: Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet, 337(8753), 1304-8 (1991).
146. R. Squitti, P. M. Rossini, E. Cassetta, F. Moffa, P. Pasqualetti, M. Cortesi, A. Colloca, L. Rossi and A. Finazzi-Agro: d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest, 32(1), 51-9 (2002). (Pubitemid 36228383)
147. C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q. X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi and C. L. Masters: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60(12), 1685-91 (2003). (Pubitemid 37521621)
148. B. Regland, W. Lehmann, I. Abedini, K. Blennow, M. Jonsson, I. Karlsson, M. Sjogren, A. Wallin, M. Xilinas and C. G. Gottfries: Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord, 12(6), 408-14 (2001). (Pubitemid 34701665)
149. B. Ibach, E. Haen, J. Marienhagen and G. Hajak: Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report. Pharmacopsychiatry, 38(4), 178-9 (2005). (Pubitemid 41065045)
150. C. Treiber, A. Simons, M. Strauss, M. Hafner, R. Cappai, T. A. Bayer and G. Multhaup: Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem, 279(50), 51958-64 (2004). (Pubitemid 39656565)
151. A. R. White, T. Du, K. M. Laughton, I. Volitakis, R. A. Sharples, M. E. Xilinas, D. E. Hoke, R. M. Holsinger, G. Evin, R. A. Cherny, A. F. Hill, K. J. Barnham, Q. X. Li, A. I. Bush and C. L. Masters: Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent upregulation of metalloprotease activity. J Biol Chem, 281(26), 17670-80 (2006). (Pubitemid 44035565)
152. P. A. Adlard, R. A. Cherny, D. I. Finkelstein, E. Gautier, E. Robb, M. Cortes, I. Volitakis, X. Liu, J. P. Smith, K. Perez, K. Laughton, Q. X. Li, S. A. Charman, J. A. Nicolazzo, S. Wilkins, K. Deleva, T. Lynch, G. Kok, C. W. Ritchie, R. E. Tanzi, R. Cappai, C. L. Masters, K. J. Barnham and A. I. Bush: Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 59(1), 43-55 (2008). (Pubitemid 351905863)
153. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C. L. Masters, S. Targum, A. I. Bush, R. Murdoch, J. Wilson and C. W. Ritchie: Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol, 7(9), 779-86 (2008).
154. J. Constantinidis: Treatment of Alzheimer's disease by zinc compounds. Drug Development Research, 27(1), 1-14 (1992).
155. K. J. Barnham, W. J. McKinstry, G. Multhaup, D. Galatis, C. J. Morton, C. C. Curtain, N. A. Williamson, A. R. White, M. G. Hinds, R. S. Norton, K. Beyreuther, C. L. Masters, M. W. Parker and R. Cappai: Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem, 278(19), 17401-7 (2003). (Pubitemid 36799626)
156. G. Multhaup, A. Schlicksupp, L. Hesse, D. Beher, T. Ruppert, C. L. Masters and K. Beyreuther: The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science, 271(5254), 1406-9 (1996). (Pubitemid 26089474)
157. A. I. Bush, W. H. Pettingell, G. Multhaup, M. d Paradis, J. P. Vonsattel, J. F. Gusella, K. Beyreuther, C. L. Masters and R. E. Tanzi: Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 265(5177), 1464- 7 (1994). (Pubitemid 24306803)
158. K. J. Barnham, G. D. Ciccotosto, A. K. Tickler, F. E. Ali, D. G. Smith, N. A. Williamson, Y. H. Lam, D. Carrington, D. Tew, G. Kocak, I. Volitakis, F. Separovic, C. J. Barrow, J. D. Wade, C. L. Masters, R. A. Cherny, C. C. Curtain, A. I. Bush and R. Cappai: Neurotoxic, redoxcompetent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem, 278(44), 42959-65 (2003). (Pubitemid 37345908)
159. C. S. Atwood, R. C. Scarpa, X. Huang, R. D. Moir, W. D. Jones, D. P. Fairlie, R. E. Tanzi and A. I. Bush: Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolaraffinity copper binding site on amyloid beta1-42. J Neurochem, 75(3), 1219-33 (2000). (Pubitemid 30660512)
160. A. R. White, G. Multhaup, F. Maher, S. Bellingham, J. Camakaris, H. Zheng, A. I. Bush, K. Beyreuther, C. L. Masters and R. Cappai: The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci, 19(21), 9170-9 (1999). (Pubitemid 30228069)